Skip to main content
Erschienen in: Clinical Journal of Gastroenterology 2/2020

26.09.2019 | Case Report

Barrett’s adenocarcinoma with esophageal varices successfully treated by endoscopic submucosal dissection with direct varices coagulation

verfasst von: Chise Ueda, Tetsuya Yosizaki, Norio Katayama, Norihiro Okamoto, Hiroki Hashimura, Masanori Matsumoto, Megumi Takagi, Seitaro Ikeoka, Kenji Momose, Takaaki Eguchi, Hiroshi Yamashita, Akihiko Okada

Erschienen in: Clinical Journal of Gastroenterology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

A 67-year-old Japanese man with alcoholic cirrhosis underwent esophagogastroduodenoscopy (EGD), which revealed a 15-mm elevated lesion on the esophagogastric junction (EGJ). Endoscopic findings suggested that the lesion was an intramucosal cancer present on the esophageal varices. The location of the lesion at EGJ caused difficulties in endoscopic injection sclerotherapy and endoscopic variceal ligation for esophageal varices before esophageal endoscopic submucosal dissection (ESD). Direct varices coagulation treatment was therefore selected during ESD. Coagulation of bared varices with hemostatic forceps after mucosal incision enabled performing ESD without serious bleeding. 2 months afterwards, the patient underwent EGD, with no esophageal varices or carcinoma recurrence. Direct varices coagulation was effective for ESD of Barrett adenocarcinoma with esophageal varices.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Tachibana M, Kotoh T, Kinugasa S, et al. Esophageal cancer with cirrhosis of the liver: results of esophagectomy in 18 consecutive patients. Ann Surg Oncol. 2000;7:758–63.CrossRef Tachibana M, Kotoh T, Kinugasa S, et al. Esophageal cancer with cirrhosis of the liver: results of esophagectomy in 18 consecutive patients. Ann Surg Oncol. 2000;7:758–63.CrossRef
2.
Zurück zum Zitat Trivin F, Boucher E, Vauleon E, et al. Management of esophageal carcinoma associated with cirrhosis: a retrospective case-control analysis. J Oncol. 2009;2009:173421.CrossRef Trivin F, Boucher E, Vauleon E, et al. Management of esophageal carcinoma associated with cirrhosis: a retrospective case-control analysis. J Oncol. 2009;2009:173421.CrossRef
3.
Zurück zum Zitat Kim JS, Kim BW, Shin IS. Efficacy and safety of endoscopic submucosal dissection for superficial squamous esophageal neoplasia: a meta-analysis. Dig Dis Sci. 2014;59:1862–9.CrossRef Kim JS, Kim BW, Shin IS. Efficacy and safety of endoscopic submucosal dissection for superficial squamous esophageal neoplasia: a meta-analysis. Dig Dis Sci. 2014;59:1862–9.CrossRef
4.
Zurück zum Zitat Mitsuishi T, Goda K, Imazu H, et al. Superficial esophageal carcinomas on esophageal varices treated with endoscopic submucosal dissection after intravariceal endoscopic injection sclerotherapy. Gastroenterol Endosc. 2013;55:2189–96. Mitsuishi T, Goda K, Imazu H, et al. Superficial esophageal carcinomas on esophageal varices treated with endoscopic submucosal dissection after intravariceal endoscopic injection sclerotherapy. Gastroenterol Endosc. 2013;55:2189–96.
5.
Zurück zum Zitat Tsou YK, Liu CY, Fu KI, et al. Endoscopic submucosal dissection of superficial esophageal neoplasms is feasible and not riskier for patients with liver cirrhosis. Dig Dis Sci. 2016;61:3565–71.CrossRef Tsou YK, Liu CY, Fu KI, et al. Endoscopic submucosal dissection of superficial esophageal neoplasms is feasible and not riskier for patients with liver cirrhosis. Dig Dis Sci. 2016;61:3565–71.CrossRef
6.
Zurück zum Zitat Sawaguchi M, Jin M, Matsuhashi T, et al. The feasibility of endoscopic submucosal dissection for superficial esophageal cancer in patients with cirrhosis (with video). Gastrointest Endosc. 2014;79:681–5.CrossRef Sawaguchi M, Jin M, Matsuhashi T, et al. The feasibility of endoscopic submucosal dissection for superficial esophageal cancer in patients with cirrhosis (with video). Gastrointest Endosc. 2014;79:681–5.CrossRef
7.
Zurück zum Zitat Poza Cordon J, Froilan Torres C, Burgos Garcia A, et al. Endoscopic management of esophageal varices. World J Gastrointest Endosc. 2012;4:312–22.CrossRef Poza Cordon J, Froilan Torres C, Burgos Garcia A, et al. Endoscopic management of esophageal varices. World J Gastrointest Endosc. 2012;4:312–22.CrossRef
8.
Zurück zum Zitat Funakoshi K, Akiyama N, Kozakai I, et al. Successful endoscopic therapy of superficial esophageal cancer on varices in a patient with alcoholic liver cirrhosis. Dig Endosc. 2001;13:212–5.CrossRef Funakoshi K, Akiyama N, Kozakai I, et al. Successful endoscopic therapy of superficial esophageal cancer on varices in a patient with alcoholic liver cirrhosis. Dig Endosc. 2001;13:212–5.CrossRef
9.
Zurück zum Zitat Wheeler JB, Reed CE. Epidemiology of esophageal cancer. Surg Clin N Am. 2012;92:1077–87.CrossRef Wheeler JB, Reed CE. Epidemiology of esophageal cancer. Surg Clin N Am. 2012;92:1077–87.CrossRef
10.
Zurück zum Zitat Domper Arnal MJ, Ferrandez Arenas A, Lanas Arbeloa A. Esophageal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol WJG. 2015;21:7933–43.CrossRef Domper Arnal MJ, Ferrandez Arenas A, Lanas Arbeloa A. Esophageal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol WJG. 2015;21:7933–43.CrossRef
11.
Zurück zum Zitat Amadi C, Gatenby P. Barrett's oesophagus: Current controversies. World J Gastroenterol WJG. 2017;23:5051–67.CrossRef Amadi C, Gatenby P. Barrett's oesophagus: Current controversies. World J Gastroenterol WJG. 2017;23:5051–67.CrossRef
12.
Zurück zum Zitat Kawada K, Kawano T, Nakajima Y. Diagnosis of Barrett’s esophagus and Barrett’s esophageal cancer by endoscopy. Gastroenterol Endosc. 2017;59:70–80. Kawada K, Kawano T, Nakajima Y. Diagnosis of Barrett’s esophagus and Barrett’s esophageal cancer by endoscopy. Gastroenterol Endosc. 2017;59:70–80.
13.
Zurück zum Zitat Westerterp M, Koppert LB, Bunkens CJ. Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows Arch. 2005;446:497–504.CrossRef Westerterp M, Koppert LB, Bunkens CJ. Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows Arch. 2005;446:497–504.CrossRef
14.
Zurück zum Zitat Liu L, Hofstetter WL, Rashid A. Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. Am J Surg Pathol. 2005;29:1079–85.PubMed Liu L, Hofstetter WL, Rashid A. Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. Am J Surg Pathol. 2005;29:1079–85.PubMed
15.
Zurück zum Zitat Oh DS, Hagen JA, Chandrasoma PT. Clinical biology and surgical therapy of intramucosal adenocarcinoma of the esophagus. J Am Coll Surg. 2006;203:152–61.CrossRef Oh DS, Hagen JA, Chandrasoma PT. Clinical biology and surgical therapy of intramucosal adenocarcinoma of the esophagus. J Am Coll Surg. 2006;203:152–61.CrossRef
16.
Zurück zum Zitat Abraham SC, Krasinskas AM, Correa AM. Duplication of the muscularis mucosae in barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma. Am J Surg Pathol. 2007;31:1719–25.CrossRef Abraham SC, Krasinskas AM, Correa AM. Duplication of the muscularis mucosae in barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma. Am J Surg Pathol. 2007;31:1719–25.CrossRef
17.
Zurück zum Zitat Ishihara R, Oyama T, Abe S. Risk of metastasis in adenocarcinoma of the esophagus: a multicenter retrospective study in a Japanese population. J Gastroenterol. 2017;52:800–8.CrossRef Ishihara R, Oyama T, Abe S. Risk of metastasis in adenocarcinoma of the esophagus: a multicenter retrospective study in a Japanese population. J Gastroenterol. 2017;52:800–8.CrossRef
18.
Zurück zum Zitat Barbour AP, Jones M, Brown I. Risk stratification for early esophageal adenocarcinoma: analysis of lymphatic spread and prognostic factors. Ann Surg Oncol. 2010;17:2494–502.CrossRef Barbour AP, Jones M, Brown I. Risk stratification for early esophageal adenocarcinoma: analysis of lymphatic spread and prognostic factors. Ann Surg Oncol. 2010;17:2494–502.CrossRef
19.
Zurück zum Zitat Bolton WD, Hofstetter WL, Francis AM. Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2009;138:831–6.CrossRef Bolton WD, Hofstetter WL, Francis AM. Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2009;138:831–6.CrossRef
20.
Zurück zum Zitat Friedman LS. Surgery in the patient with liver disease. Trans Am Clin Climatol Assoc. 2010;121:192–204 (discussion 205).PubMedPubMedCentral Friedman LS. Surgery in the patient with liver disease. Trans Am Clin Climatol Assoc. 2010;121:192–204 (discussion 205).PubMedPubMedCentral
Metadaten
Titel
Barrett’s adenocarcinoma with esophageal varices successfully treated by endoscopic submucosal dissection with direct varices coagulation
verfasst von
Chise Ueda
Tetsuya Yosizaki
Norio Katayama
Norihiro Okamoto
Hiroki Hashimura
Masanori Matsumoto
Megumi Takagi
Seitaro Ikeoka
Kenji Momose
Takaaki Eguchi
Hiroshi Yamashita
Akihiko Okada
Publikationsdatum
26.09.2019
Verlag
Springer Singapore
Erschienen in
Clinical Journal of Gastroenterology / Ausgabe 2/2020
Print ISSN: 1865-7257
Elektronische ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-019-01048-9

Weitere Artikel der Ausgabe 2/2020

Clinical Journal of Gastroenterology 2/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.